Introduction Recently, China initiated an ambitious healthcare reform aiming to provide affordable and equitable basic health care to all by 2020. To meet these goals, new policies issued by China's Ministry of Health mandate clinical pharmacy services be integrated into China's hospitals. This review aims to highlight the impact of clinical pharmacy services on the quality use of medicines in hospitals in China.
Methods
Both English and Chinese databases were used. For the English databases, Web of Science, Medline, International Pharmaceutical Abstracts and Embase were searched using the following keywords ('pharmacists' OR 'pharmacy' OR 'pharmaceutical services/pharmaceutical care') AND ('China'). For the Chinese database, Chinese Biomedical Literature Database on disc was searched using the following keywords ('clinical pharmacist' OR 'clinical pharmacy' OR 'pharmaceutical care' OR 'pharmaceutical services'). Articles were then retrieved from WanFang database and China Knowledge Resource Integrated Database.
Results
A total of 75 published papers were included in this review. The majority of studies were conducted in the inpatient setting (68%), which included clinical pharmacy interventions such as educating doctors and patients, evaluating and monitoring the implementation of hospital policies and/or reviewing medications on the ward. In the outpatient setting, the majority of studies conducted involved educating patients. Clinical pharmacy services frequently focused on antimicrobials (44%). More than half of these studies employed an administrative intervention alongside the clinical pharmacy service.
Introduction
Irrational prescribing is a global concern with the World Health Organization (WHO) estimating that up to half of all medications prescribed or received by patients are inappropriate (WHO 2002) . As a result, the WHO has strongly promoted their rational drug use programme based on essential medicines (WHO 2002) and their guide to good prescribing (De Vries et al. 1994) . Furthermore, overprescribing of antimicrobials in particular has caused large concerns due to growing rates of antimicrobial resistance worldwide (WHO 2001) . This has led groups such as the WHO and ReAct-Action on Antibiotic Resistance to continually ensure appropriate antimicrobial use is on the international agenda (WHO 2001; ReAct 2013) . In line with these global initiatives, China has recently initiated an ambitious healthcare reform aiming to provide affordable and equitable basic health care to all by 2020 (Yip et al. 2012) . This reform focuses on public hospitals, which deliver more than 90% of China's inpatient and outpatient services (Ministry of Health of the People's Republic of China (MoH) 2011a). To meet these goals, new policies issued by the MoH surrounding the accreditation of tertiary hospitals (MoH 2011b) and antimicrobial use in hospitals (MoH 2011c) mandate clinical pharmacy services be integrated into China's hospitals. Internationally, the development of clinical pharmacy services has expanded the role of a pharmacist from the traditional product-focused role to a patient-focused one (Anderson 2002; Nissen 2009 ). American College of Clinical Pharmacy (ACCP) (2008) states 'Clinical pharmacy is a health science discipline in which pharmacists provide patient care that optimizes medication therapy and promotes health, wellness and disease prevention'. Australia defines it as 'the practice of pharmacy as part of a multi-disciplinary healthcare team directed at achieving Quality Use of Medicines' (Dooley et al. 2005) , while the European Society of Clinicial Pharmacy (2010) defines it as 'a health specialty, which describes the activities and services of the clinical pharmacist to develop and promote the rational and appropriate use of medicinal products and devices'. Despite nuances in definitions, all focus on providing patient-focused care and promoting high quality and rational use of medications.
Clinical pharmacy services have been shown to facilitate appropriate prescribing, prevent adverse drug events, reduce medication errors, reduce patients' length of stay, lower mortality and reduce costs (Schumock et al. 1996 (Schumock et al. , 2003 Bond et al. 2000 Bond et al. , 2002 Kaboli et al. 2006; Pickard and Hung 2006; Bond and Raehl 2007; De Rijdt et al. 2008; MacLaren et al. 2008; Perez et al. 2008; Anderson and Schumock 2009 ). Clinical pharmacy services have been implemented in a variety of different specialties in the hospital setting where multidisciplinary collaboration is already established and patient data are readily available (Ibrahim et al. 2001; Papadopoulos et al. 2002; Kane et al. 2003; Horn and Jacobi 2006) . As a result, pharmacists within the hospital have shifted from the dispensary to the ward and clinic setting (Anderson 2002) . While clinical pharmacy services are not limited to the hospital setting, this is where the bulk of practice and research have been conducted , 2008 Anderson and Schumock 2009) .
International Pharmaceutical Federation (2009) are international consensus statements reflecting the pharmacy profession's vision for hospital pharmacy practice. Produced by the International Pharmaceutical Federation (FIP), these statements acknowledge the desired advancement of clinical pharmacy services globally. For example, statement 65 states: 'Advanced clinical pharmacy services should manage medication therapy to optimize therapeutic outcomes.' Clinical pharmacy services are firmly established in many developed countries (Pedersen et al. 2011; Musing 2013) and are being embraced by many developing countries (Pande et al. 2013) . Although numerous countries in the Asian region have started to implement clinical pharmacy services, they have often been hospital-dependent with different levels of services provided (Pande et al. 2013) . China is one of the first countries in this region to mandate these services in all secondary and tertiary hospitals.
Clinical pharmacy services in China
China became interested in clinical pharmacy services as early as 1962 (Liu 1982) ; however, implementation of services halted during the Cultural Revolution (Liu 1982; Richards 1984) . Clinical pharmacy was revisited in the early 1980s with many Chinese pharmacists training overseas (Liu 1982) , as well as international academics being invited to China (Richards 1984; Richards 1990 ). West China Medical University, now Sichuan University, developed the first 5-year clinical pharmacy degree in 1989. However, due to the economic and political climate, clinical pharmacy was seen as impractical at the time and the programme was abolished in 1998 (Ryan et al. 2008; Jiang et al. 2011) . In 2001, clinical pharmacy education was redeveloped by Peking University, offering a 6-year dual Bachelor and Master programme in clinical pharmacy (Ryan et al. 2008) . The first cohort of 15 graduated in 2007 (Ryan et al. 2008) . To implement the new policies accompanying the current reform in China (MoH 2011b,c,d) more formally trained clinical pharmacists may be required. In fact, in light of this, the pharmacy education system in China now has at least 26 universities offering clinical pharmacy education (Ryan et al. 2008) .
Clinical pharmacy services and the healthcare reform in China
China's healthcare reform aims to control China's increasing health expenditure to provide affordable health care (Yip et al. 2012) . The public hospital sector in particular is a key focus as they have received limited government funds since the economic reforms in 1985. It is estimated that 90% of public hospitals' revenue is currently generated directly from patients for medications and tests (Hsiao 2008; Alcorn and Bao 2011) . Furthermore, medications alone account for over 50% of this revenue (Anonymous 2010; Yip et al. 2012) . This has led to a perception of inappropriate prescribing. Reynolds and McKee (2009) claimed two forms of financial incentives to prescribe existed in China: 'One was created by pharmaceutical companies, who sometimes arrange to split profits with prescribers, illegally and covertly, while the other emanated from all health providers, which are entitled to make a 15% profit on sales to fund services.' As a result, over-prescribing has become a concern in the context of China's increasing healthcare expenditure (Yip et al. 2012) .
One strategy to reduce China's healthcare expenditure is to improve the quality use of medications through clinical pharmacy services (Ryan et al. 2008) . The MoH conducted a pilot programme to introduce clinical pharmacists in 50 hospitals from to 2008 (MoH 2007 . At the conclusion of this pilot, nearly all directors of hospitals, doctors, patients and pharmacy directors surveyed (n ¼ 207) supported the role of clinical pharmacists (Committee for pharmacy administration and Chinese hospital association 2009). As a result, in 2011, the MoH issued a policy that all secondary and tertiary hospitals should have three and five full-time clinical pharmacists, respectively (MoH 2011d).
Antimicrobial stewardship has provided a platform for initiation of clinical pharmacy services in China, as antimicrobial resistance is of major concern Yao and Yang 2008) . From 1999 to 2001, the prevalence of resistance among hospital-acquired Staphylococcus aureus infections was 77% and Streptococcus pneumonia was over 80% (Yao and Yang 2008) and on the rise (MoH 2011c). Accordingly, the MoH released a series of campaigns and policies (MoH 2011c (MoH , 2012a stating that all secondary and tertiary hospitals should have clinical pharmacists trained in infectious diseases. Furthermore, these trained pharmacists are able to give guidance and approval for restricted antimicrobial use (MoH 2011c) . This highlights the important contribution clinical pharmacy services have on antimicrobial stewardship as per international practices (Paskovaty et al. 2005) .
New contribution
Clinical pharmacy services, while still in early stages of development, are becoming firmly established with the support of China's MoH. While the MoH in China is dedicated to advancing clinical pharmacy services, this movement cannot be solely based on emulating services provided in other countries (Committee for pharmacy administration and Chinese hospital association 2009). It cannot be assumed that studies conducted in other countries are transferable to China. To ensure clinical pharmacy services are relevant to the needs of China and implemented effectively, local literature and research data are necessary. Previous literature reviews on clinical pharmacy services have excluded the vast literature in China as they have limited their search to the English language (Hatoum et al. 1986; Schumock et al. 1996 Schumock et al. , 2003 Kaboli et al. 2006; Pickard and Hung 2006; De Rijdt et al. 2008; Perez et al. 2008) .
This literature review is the first of its kind, as it reviews the Chinese academic literature, translating and presenting a narrative of its content to the English-speaking world. The aim of this literature review focused on the impact of clinical pharmacy services in hospitals in China.
Methods

Search strategy
The English databases Web of Science, Medline, International Pharmaceutical Abstracts (IPA) and Embase were searched using the following key words ('pharmacists' OR 'pharmacy' OR 'pharmaceutical services/pharmaceutical care') AND ('China').
The Chinese database Chinese Biomedical Literature Database on disc (CBMDISC) was searched using the following key words ('clinical pharmacist' OR 'clinical pharmacy' OR 'pharmaceutical care' OR 'pharmaceutical services'). Articles were then retrieved from WanFang database and China Knowledge Resource Integrated Database.
Articles published in English or Chinese up to June 1, 2012 were included (Appendix 1).
Study selection
Measurable impact of clinical pharmacy services in China was explored. Original research studies that included intervention/s from a hospital pharmacist and reported a comparative outcome before and after the intervention were included.
Papers identified in the Chinese database were included if they were listed in the 2011 Institute of Scientific and Technical (S&T) Information of China (2012a) Core Journal List. Papers in this list are chosen through strict selection criteria for quality by the Institute of Chinese Scientific and Technical (S&T) Information of China (2012b). Studies were excluded if they were conducted in Taiwan or Special Administrative Regions, Hong Kong and Macau. Studies were also excluded if they did not describe the intervention used, or if the hospital pharmacist did not have a defined role in the intervention.
Citations generated by the search strategy were initially screened by two authors (J.P. and Y.L.) for relevance and eligibility from the title and abstract. Potential articles were then retrieved and reviewed. The screening process was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (Figure 1 ).
Data extraction and analysis
Two investigators (J.P. and Y.L.) extracted key components of these studies using a standardized form, in consultation with other investigators (R.M. and B.C.). Relevant studies reported The following data were extracted from each relevant study: therapeutic field, study design, intervention used, major selected outcomes and results. These studies were then sorted by patient-care setting, therapeutic field and the year of publication (Table 1 ). The studies were categorized into experimental studies (randomized, pseudorandomized or cluster randomized control studies), comparative studies (concurrent, historical control studies or interrupted time series) and other observational studies (case series) as defined by the National Health and Medical Research Council of Australia (2000) .
Clinical, humanistic and economical outcomes were classified into a hierarchy adapted from the Agency for Healthcare Research and Quality (2001) as used in the systematic reviews of Chisholm-Burns et al. (2010) and Roughead et al. (2005) ( Table 2 ). This hierarchy considers Level 1 as the highest level of evidence, with lower levels relatively less reliable. If a study reported outcomes that belonged to more than one level, then the highest outcome level was registered. In addition, clinical and humanistic outcomes were grouped together, while economic outcomes were classified separately.
Results
Number of studies
The search strategy generated 4 articles in Web of Science, 3 in Medline, 3 in IPA, 1 in Embase and 238 from CBMDISC. After removal of duplicates, 242 full text papers, including 7 in English and 235 in Chinese, were retrieved and screened. Further refinement resulted in 75 studies reviewed: 5 in English and 70 in Chinese (Figure 1 ).
Setting and type of intervention
The majority of studies were conducted in the inpatient setting (68%). Four studies included both outpatient and inpatient settings, while the remaining 20 studies were in outpatient settings (Table 3) . The majority of studies conducted in inpatient settings included interventions such as pharmacists educating doctors and patients, evaluating and monitoring the implementation of hospital policies and/or reviewing medications on the ward. The majority of studies conducted in outpatient settings involved educating patients.
Studies were classified according to the therapeutic field of clinical pharmacy service (Table 4) . Clinical pharmacy services frequently focused on antimicrobials (44%), with 28 focused on surgical prophylaxis. Eleven studies focused on prescriptions with no specified specialty and were classified as general medicine. Seven studies focused on specific medications such as warfarin, quinolones, benzodiazepines and aspirin.
Of the 75 studies, 33 included a multimodal approach, with an additional intervention alongside clinical pharmacy services. Additional interventions included an administrative intervention (AI) or additional services offered by other healthcare professionals (HCP). Of the 33 studies that focused on antimicrobial use, 23 employed an AI alongside the clinical pharmacy intervention. Additional HCP interventions were used Interrupted time series Clinical pharmacists facilitated the rational use of antimicrobials in conjunction with AI.
Antimicrobial use (inpatient)
Prescriptions with an appropriate antimicrobial for surgery increased from 64.0% to 82.0% (P: NR)
Xu and Ge (2010) Historical control study Rate of surgical site infections remained the same from 10% to 11.49% (P: NS)
Zhu ( Su (2011) Interrupted time series Prescriptions with an appropriate dosing time increased from 81% to 94.5% (P < 0.001)
Pharmacists may have helped to facilitate the rational use of antimicrobials in conjunction with AI.
Antimicrobial use in oncol-
Prescriptions with an appropriate antimicrobial increased from 71% to 94% (P < 0.001) (continued) Patients with asthma were counselled on the importance of therapy, correct inhaler technique and peak flow monitoring. Patients' progress was followed and adherence monitored.
Patients adherent to their medications:
Clinical pharmacists improved patients' adherence.
Asthma (inpatient and outpatient) At T0 was 30.0% (I) vs 33.3% (C) (P: NS) At T1 was 60% (I) vs 40% (C) (P < 0.05) At T2 was 56.7% (I) vs 30.0% (C) (P < 0.05) Lang and Zhang (2005) Pre-post case series study 6-month follow-up Pharmacists compiled pharmacy records, provided counselling and gave lectures to patients. Patients were also followed up with phone calls or home visits. Self-reported adherence was 90% (I) vs 76.7% (C) (P: NR) Although no statistics were reported, pharmacists appear to have improved patients' outcomes and adherence.
Diabetes mellitus (outpatient)
Patients average HbA1c was 6.18% (I) vs 6.64% (C) (P: NR) Zhao et al. (2010) Randomized control study
3-month follow-up. Pharmacist provided patient education to all patients on enrolment.
Monthly text messages were sent regarding their medications and disease. Patients were also able to send text messages back for further information.
Satisfaction rate of patients was 93.3%
Although patients are satisfied with text message services provided, pharmacists did not appear to improve outcomes.
Diabetes mellitus (inpatient and outpatient)
Fasting blood glucose was 6.89% mmol/l (I) vs 6.96% mmol/l (C) (P: NS)
2-h post-prandial blood glucose was 8.72 mmol/l (I) vs 8.84 mmol/l (C) (P: NS) (continued) 
Patients who knew their blood glucose level increased from 74.11% to 97.55% (P < 0.01)
Patients whose blood glucose level was within their target range increased from 47.14% to 89.62% (P < 0.01)
Nie ( Pharmacists improved patients' outcomes and adherence.
Hypertension (outpatients)
Patients whose blood pressure was within target range increased from 6.6% to 51.3% (P < 0.01) Zhao et al. (2012) Randomized control study
6-month follow-up Clinical pharmacists counselled patients on their disease and medication, monitored for ADRs and followed up the patients' therapeutic plan. Patients whose blood pressure was within target range were 76.4% (I) vs 50.6% (C) (P < 0.001)
Clinical pharmacist improved patients' outcome, adherence and medication knowledge.
Hypertension ( in seven studies that mainly included education provided to patients by a pharmacist.
Study designs and hierarchy of study outcomes
The majority of studies used a comparative study design (61%), whereas the remaining adopted either experimental or observational designs (Table 3) . For clinical and humanistic outcomes, about half of the studies reported Level 1 or 2 outcomes (47%). For Level 1 outcomes in the inpatient setting, clinical pharmacy services were associated with a decrease in the patient's readmission rates and adverse drug reaction (ADR) rates. For the outpatient setting, clinical pharmacy services were associated with a decreased rate of relapse for patients with depression or schizophrenia, and a decreased rate of ulcerations for patients with ulcerative colitis.
For economic outcomes, most studies (79%) reported Level 3 outcomes. None of the included studies evaluated the cost effectiveness, cost utility or cost benefit of clinical pharmacy services. For Level 2 outcomes, clinical pharmacy services were associated with a lower medication costs per patient.
Trends in publication types
Numbers and types of publications were plotted over time (Figure 2) . The number of studies published increased exponentially from 3 papers in 2005 to 24 papers in 2011. Recently, more studies focusing on antimicrobial use were published, corresponding to the release of policy documents (Figure 2 ).
Discussion
Provision of clinical pharmacy services is the future direction of hospital pharmacists, as stated in International Pharmaceutical Federation (2009). With China's rapidly growing economy and (Ryan et al. 2008; Cao et al. 2009; Xie et al. 2010; Shen et al. 2011; Zhang et al. 2012a; Zhao et al. 2012) , this is the first time the Chinese literature regarding this topic has been comprehensively translated and reviewed in English. This review reveals that clinical pharmacy services have resulted in beneficial outcomes in Chinese hospitals. This review revealed that China has implemented clinical pharmacy services in a range of inpatient and outpatient settings. Clinical pharmacy services appear to enhance appropriate prescribing and patient understanding of medications, despite doctors' incentives to overprescribe (Zhang and Harvey 2006; Reynolds and McKee 2009; Anonymous 2010) . The most successful interventions involved antimicrobial stewardship with both pharmacy and AI. These studies reflect the key messages contained in the 'Policy on the clinical use of antimicrobials' (MoH 2011c) and the number of publications focusing on antimicrobials appear to have increased since its release (Figure 2 ). This antimicrobial policy is the first to mandate clinical pharmacy services, and may be a powerful catalyst to include clinical pharmacy in future policies in other clinical areas.
Nearly all studies reported that clinical pharmacy services positively influenced clinical and humanistic outcomes by increasing appropriate use of medication, patient knowledge, quality of life, adherence and reducing patient length of stay. Two studies found no significant effect of clinical pharmacy services on surrogate markers in the outpatient setting on patients with diabetes (Pan and Liu 2009; Zhao et al. 2010) . However, both studies followed patients for only 3 months. A follow-up period of at least 6-12 months may be required to produce beneficial effects as seen in Li et al. (2008) and Huang and Ma (2011) .
The types of studies included in this review, however, were primarily comparative design trials with only 28% having a randomization process. Previous literature reviews in the English language generally had 60-70% of studies with experimental study designs (Kaboli et al. 2006; Pickard and Hung 2006) . As China has only recently implemented clinical pharmacy services, few pharmacy researchers in China would have had the opportunity to conduct experimentally designed studies. Although conducting more studies with experimental design in China will allow more reliable conclusions to be made, the current comparative designs show promising results highlighting the sustainability and efficacy of clinical pharmacy services in China.
Regarding the impact of clinical pharmacy services, many studies showed a decrease in: adverse drug events; reactions; inappropriate prescriptions; length of stay; and both pharmacy and hospital costs. This is consistent with previous literature reviews in the English language (Schumock et al. 1996 (Schumock et al. , 2003 De Rijdt et al. 2008; Perez et al. 2008) . However, none of the studies included in this review reported how much money was invested to implement the clinical pharmacy services. Although cost savings were demonstrated, the return on investment could not be determined. Although the studies demonstrated that clinical pharmacy services do have a clinical, humanistic and economical impact, further research is required to identify if such services are sustainable and provide a reasonable return on investment in China.
Assessing clinical pharmacy services' economical impact will be critical for the future of China's healthcare reform, which endeavours to address the current system where patients contribute up to 90% of hospitals' revenue (Alcorn and Bao 2011) . Although the method of delivering this reform is heavily debated and numerous methods are being piloted, hospitals will be encouraged to decrease expenditure by following clinical protocols and appropriate prescribing (Yip et al. 2012) . Hospital pharmacists in China seem well placed to assist, and their success in antimicrobials forecasts the valuable contribution they can make. More reliable studies focusing on the cost effectiveness of clinical pharmacy services in China will provide reliable data to further support implementation of clinical pharmacy in China.
Previous literature reviews have highlighted that implementing clinical pharmacy services does not always require additional funds but can occur by the reallocation of existing resources (Kaboli et al. 2006) . Internationally, pharmacy technicians and adoption of technology, such as automated dispensing, have allowed pharmacists to be more involved in clinical pharmacy services and reduce costs (Kaboli et al. 2006; Bond and Raehl 2008) . However, in China few pharmacy technicians to assist with dispensing and stocking exist. Employment of pharmacy technicians in Chinese hospitals and further adoption of technology may allow more 
Strengths and limitations
This review is the first insight into the Chinese literature, reported in the English language, which highlights the impact of hospital pharmacy services. China's new reforms, in favour of adopting clinical pharmacy services in public hospitals, clearly appear to be integrating International Pharmaceutical Federation (2009). This review also provides a view of the reforms China is undertaking in line with global standards of practice in health care, from a pharmacy perspective.
Conclusions of the studies reviewed were, however, limited by their design, some using multiple interventions simultaneously and many unable to offer Level 1 evidence. Comparable limitations in study design have been identified in similar reviews (Kaboli et al. 2006; De Rijdt et al. 2008) . Many studies had small sample sizes or failed to undertake sample size calculations. Most studies were only conducted in a single hospital or ward, limiting generalizability. Little information was given on the exact nature of the interventions implemented, making it difficult to compare results and preventing meta-analysis. Economic evaluations often focused on direct healthcare costs only, excluding pharmacy labour costs and did not use incremental cost analysis. Finally, although all efforts have been made, due to the nature of systematic reviews and potential defects in search strategy, it cannot be guaranteed that all relevant articles published were included.
Nonetheless, this review demonstrated that clinical pharmacy services appear to positively influence patient care and appropriate use of medications within China's unique healthcare system and cultural environment.
Conclusion
From the published literature, it can be elucidated that clinical pharmacy services can make a valuable contribution to China's healthcare reform. In order for this to be achieved more government, education and administrative support may need to be cultivated.
